Lilly Sues Accord Over Gemzar ANDA

Law360, New York (October 20, 2010, 4:04 PM EDT) -- Eli Lilly & Co. has sued Intas Pharmaceutical Ltd. marketing arm Accord Healthcare Inc. over its attempt to introduce a generic version of Gemzar, marking the drug giant's latest move to fend off competition for the cancer treatment.

The complaint, filed Tuesday in the U.S. District Court for the Middle District of North Carolina, claims Accord has infringed a Lilly patent by trying to obtain regulatory approval to import and sell generic Gemzar.

Accord’s submission of an abbreviated new drug application for gemcitabine hydrochloride constitutes infringement...
To view the full article, register now.